When was Hexem bio founded?

Hexem bio was founded in 2024 and raised its 1st funding round 2 years after it was founded.

Where is Hexem bio located?

Hexem bio is headquartered in New York City, United States.

Who is the current CEO of Hexem bio?

Gabriel Levesque Tremblay of Hexem bio. They have also founded 2 companies.

How many employees does Hexem bio have?

As of Sep 30, 2026, the latest employee count at Hexem bio is 11.

Is Hexem bio a funded company?

Hexem bio is a funded company, having raised a total of $10.4M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 2026.

When was the latest funding round of Hexem bio?

Hexem bio's latest funding was a $***** Seed round on Apr 07, 2026, with participation from 3 investors. Its primary sector is Cell Therapy. In United States, the Cell Therapy sector has seen $1.05B in funding in 2026 to date.

Where does Hexem bio rank among its competitors?

Hexem bio ranks 3rd amongst 7 active competitors, of which 3 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Retro, which secured an undisclosed amount in May, 2026.

Who are the top competitors of Hexem bio?

Hexem bio's top competitors include Retro, HemoGenyx and PK MED. Among them, Retro secured the most recent funding round in May, 2026.

Hexem bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of stem cell-based therapies for aging and disease prevention. It has a cell restoration technology aimed at recording early human development for longevity. It offer therapies by rejuvenating Hematopoietic Stem Cells for bone marrow transplant failure which is a life-threatening condition.

Key Metrics

Founded Year

2024

Location

New York City, United States

Stage

Seed

Total Funding

$10.4M in 2 rounds

Latest Funding Round

Seed, Apr 07, 2026, $*****

Investors

Draper & 6 more

Ranked

3^rd among 7 active competitors

Employee Count

11 as on Sep 30, 2026

Similar Companies

Retro & 5 more

View Hexem bio's full profile

Hexem bio has raised a total funding of $10.4M over 2 rounds. Its first funding round was on Apr 2026. Its latest funding round was a Seed round on Apr 07, 2026 for $*****. 3 investors participated in its latest round. Hexem bio has 7 institutional investors.

Here is the list of recent funding rounds of Hexem bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 07, 2026	4270912	Seed	4004827	8780139	5216522	6475273
Apr 2026	5598712	Seed	3131899	2239501	2613990	Cerdwen

Access funding benchmarks and valuations. Sign up today!

View details of Hexem bio's funding rounds and investors

The founders of Hexem bio are Gabriel Levesque Tremblay, Mo Ebrahimkhani, Samira Kiani and Joshua Hislop. Gabriel Levesque Tremblay is the CEO of Hexem bio.

Here are the details of Hexem bio's key team members:

Gabriel Levesque Tremblay: Co-Founder & CEO of Hexem bio and founder of 1 other company.
Contact Info: 1 email address
Mo Ebrahimkhani: Co-Founder of Hexem bio and founder of 1 other company.
Contact Info: 2 email addresses
Samira Kiani: Co-Founder of Hexem bio and founder of 1 other company.
Contact Info: 1 email address and 1 phone number
Joshua Hislop: Co-Founder of Hexem bio.
Contact Info: 1 email address

View details of Hexem bio's Founder profiles and Board Members

Hexem bio's employee count trend

Hexem bio has 11 employees as of Sep 26. Here is Hexem bio's employee count trend over the years:

Uncover Hexem bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hexem bio include Retro, HemoGenyx and PK MED. Here is the list of Top 10 competitors of Hexem bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Retro 2020, Redwood City (United States), Series A	Developer of therapeutics targeting cellular mechanisms to treat aging diseases	$180M	4P CAPITAL & 1 others	61/100
2nd	HemoGenyx 2014, Buffalo (United States), Public	Developer of cell and gene therapies to treat blood diseases and viral infections	-	Design Technologies, 43North & 3 others	57/100
3rd	Hexem bio 2024, New York City (United States), Seed	Developer of stem cell-based therapies for aging and disease prevention	$10.4M	Draper, Seraphim & 5 others	47/100
4th	PK MED 2019, Paris (France), Seed	Developer of implants for drug delivery and tissue regeneration	$1.63M	Bpifrance, Truffle Capital	47/100
5th	Kiadis Pharma 1997, Amsterdam (Netherlands), Acquired	Developer of cell-based immunotherapy products for the treatment of blood cancers	$33M	Kreos Capital, Life Sciences Partners & 7 others	45/100
6th	Magenta Therapeutics 2016, Cambridge (United States), Public	Developer of stem cell-based therapies for autoimmune disease, genetics blood disorders and cancer	$150M	Atlas Venture, Google Ventures & 7 others	42/100
7th	Inograft Biotherapeutics 2022, Redwood City (United States), Funding Raised	Developer of non-genotoxic conditioning regimens for hematopoietic stem cell transplantation	-	Arch Venture Partners	24/100